Sorrento Announced Independent Study Shows Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX vs Globally Leading Rapid Antigen Test
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) today announced impressive results from an independent study conducted under real-world field conditions by INMEGEN (The Institute of National Genomics Medicine, Mexico).
Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
Second site scheduled to start enrolling within one week, with multiple additional sites coming online within
Sorrento Reports Exercised Exclusive Option Deal With Texas A&M University For Main Protease Inhibitors Against Sars-CoV-2, All Variants
Exclusive license for MPro inhibitors supports rapidly growing small molecule development portfolio for combating COVID-19.
Lead compound, MPI8, exhibited potent in vitro antiviral activity against SARS-CoV-2 and all
Sorrento’s mRNA COVID-19 Vaccine Shows Efficacy In Preclinical Study
Sorrento Therapeutics Inc (NASDAQ:SRNE) has announced preclinical results for its mRNA-based COVID-19 vaccine against SARS-CoV-2. STI-mRNA includes a…
Sorrento Reports Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device
Sorrento's mRNA vaccine ("STI-mRNA") delivered with the MuVaxx™ Lymphatic Drug Delivery Device ("MuVaxx"), at 1/10th of the dose vs an LNP-mRNA reference
Sorrento In-Licenses COVID-19 Targeted MPro Inhibitors
Sorrento Therapeutics Inc (NASDAQ:SRNE) has entered into an option agreement with The Texas A&M University System for exclusive rights to highly potent main…
Sorrento Therapeutics Announces Entry Into Option Agreement To Exclusively License MPRO Inhibitors Against SARS-CoV-2 And Variants Of Concern, Including Delta, From Texas A&M University
Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced that it has entered into an option agreement ("Option") with The Texas A&M University System ("TAMUS") for
Sorrento Highlights Publication Of Initial Results Of SOFUSA Lymphatic Drug Delivery System In A Phase 1b Rheumatoid Arthritis Study Using Enbrel
Rheumatoid Arthritis (RA) is one of many chronic autoimmune conditions affecting over 20 million people in the United States (NIH, 2017).
Sofusa is a revolutionary technology which delivers biologic therapies
Sorento Therapeutics Shares Move Lower; Traders Circulate TipRanks Article Titled ‘Will Sorrento’s Promising COVID-19 Vaccine Results Boost Stock?’
https://blog.tipranks.com/will-sorrentos-promising-covid-19-vaccine-results-boost-stock/